Savvy Advisors Inc. Buys Shares of 2,711 AstraZeneca PLC (NASDAQ:AZN)

Savvy Advisors Inc. purchased a new position in shares of AstraZeneca PLC (NASDAQ:AZN) during the third quarter, Holdings Channel.com reports. The fund purchased 2,711 shares of the company’s stock, valued at approximately $211,000.

Several other hedge funds have also made changes to their positions in AZN. Sumitomo Mitsui Trust Group Inc. lifted its position in AstraZeneca by 13.1% in the 3rd quarter. Sumitomo Mitsui Trust Group Inc. now owns 84,511 shares of the company’s stock valued at $6,584,000 after purchasing an additional 9,795 shares during the last quarter. Harbour Investments Inc. raised its holdings in shares of AstraZeneca by 1.9% during the third quarter. Harbour Investments Inc. now owns 8,805 shares of the company’s stock valued at $686,000 after buying an additional 160 shares during the last quarter. Nations Financial Group Inc. IA ADV raised its holdings in shares of AstraZeneca by 5.2% during the third quarter. Nations Financial Group Inc. IA ADV now owns 5,368 shares of the company’s stock valued at $418,000 after buying an additional 267 shares during the last quarter. Venturi Wealth Management LLC boosted its position in shares of AstraZeneca by 13.0% during the third quarter. Venturi Wealth Management LLC now owns 25,796 shares of the company’s stock worth $2,010,000 after buying an additional 2,968 shares during the period. Finally, Addison Advisors LLC grew its holdings in AstraZeneca by 11.9% in the 3rd quarter. Addison Advisors LLC now owns 1,743 shares of the company’s stock worth $136,000 after buying an additional 186 shares in the last quarter. Institutional investors own 20.35% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts have weighed in on the company. Deutsche Bank Aktiengesellschaft raised AstraZeneca from a “sell” rating to a “hold” rating in a research note on Wednesday, November 6th. Erste Group Bank upgraded shares of AstraZeneca from a “hold” rating to a “buy” rating in a research note on Wednesday, September 11th. Finally, TD Cowen increased their target price on shares of AstraZeneca from $90.00 to $95.00 and gave the company a “buy” rating in a research report on Monday, August 12th. Two investment analysts have rated the stock with a hold rating, seven have given a buy rating and two have assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Buy” and an average price target of $89.75.

AstraZeneca Price Performance

NASDAQ AZN opened at $65.29 on Thursday. The stock has a market capitalization of $202.44 billion, a P/E ratio of 31.24, a P/E/G ratio of 1.21 and a beta of 0.47. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.69 and a current ratio of 0.89. The business’s fifty day moving average is $76.20 and its two-hundred day moving average is $78.47. AstraZeneca PLC has a 1 year low of $60.47 and a 1 year high of $87.68.

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.